Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Seqirus,Enzalutamide,"Prostate cancer, metastatic, castration resistant, contraindicated to abiraterone",Enzalutamide (Xtandi),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
